Penumbra, Inc. (NYSE:PEN) CEO Adam Elsesser sold 62,862 shares of the stock in a transaction dated Monday, November 20th. The stock was sold at an average price of $105.15, for a total transaction of $6,609,939.30. Following the transaction, the chief executive officer now directly owns 1,191,887 shares in the company, valued at approximately $125,326,918.05. The transaction was disclosed in a filing with the SEC, which is available through this link.

Adam Elsesser also recently made the following trade(s):

  • On Friday, November 17th, Adam Elsesser sold 11,186 shares of Penumbra stock. The stock was sold at an average price of $103.56, for a total transaction of $1,158,422.16.
  • On Wednesday, November 15th, Adam Elsesser sold 24,444 shares of Penumbra stock. The stock was sold at an average price of $105.83, for a total transaction of $2,586,908.52.

Penumbra, Inc. (NYSE PEN) opened at $106.55 on Tuesday. Penumbra, Inc. has a 1 year low of $57.85 and a 1 year high of $116.35.

Penumbra (NYSE:PEN) last announced its quarterly earnings results on Tuesday, November 7th. The company reported $0.01 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.06) by $0.07. Penumbra had a negative net margin of 2.19% and a negative return on equity of 1.95%. The business had revenue of $83.90 million for the quarter, compared to analysts’ expectations of $79.17 million. During the same quarter last year, the firm earned ($0.04) EPS. The firm’s revenue for the quarter was up 24.9% compared to the same quarter last year. sell-side analysts expect that Penumbra, Inc. will post -0.15 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright law. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/11/21/penumbra-inc-pen-ceo-adam-elsesser-sells-62862-shares-of-stock.html.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Pura Vida Investments LLC lifted its position in Penumbra by 19.2% in the 3rd quarter. Pura Vida Investments LLC now owns 59,579 shares of the company’s stock valued at $5,380,000 after acquiring an additional 9,579 shares in the last quarter. Neuberger Berman Group LLC lifted its position in Penumbra by 0.8% in the 3rd quarter. Neuberger Berman Group LLC now owns 250,500 shares of the company’s stock valued at $22,620,000 after acquiring an additional 2,000 shares in the last quarter. Jane Street Group LLC bought a new position in Penumbra in the 3rd quarter valued at about $374,000. Royce & Associates LP lifted its position in Penumbra by 50.0% in the 3rd quarter. Royce & Associates LP now owns 15,000 shares of the company’s stock valued at $1,355,000 after acquiring an additional 5,000 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. lifted its position in Penumbra by 8.4% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 131,584 shares of the company’s stock valued at $11,883,000 after acquiring an additional 10,232 shares in the last quarter. 72.73% of the stock is currently owned by institutional investors and hedge funds.

A number of equities analysts have recently issued reports on the stock. Canaccord Genuity increased their price objective on shares of Penumbra from $100.00 to $113.00 and gave the stock a “buy” rating in a research report on Wednesday, November 8th. BMO Capital Markets raised their price target on shares of Penumbra from $96.00 to $117.00 and gave the company an “outperform” rating in a research report on Wednesday, November 8th. Zacks Investment Research raised shares of Penumbra from a “sell” rating to a “hold” rating in a research report on Wednesday, October 11th. Finally, BidaskClub raised shares of Penumbra from a “hold” rating to a “buy” rating in a research report on Saturday, August 12th.

About Penumbra

Penumbra, Inc is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.

Insider Buying and Selling by Quarter for Penumbra (NYSE:PEN)

Receive News & Stock Ratings for Penumbra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra Inc. and related stocks with our FREE daily email newsletter.